Anixa Biosciences: Rises on advancing development of COVID-19 antiviral candidate

Anixa Biosciences

05/04/2021 14:11

(Repeats April 5 buzz item to add Reuters Instrument Code, no
change to text, headline)
    ** Biotech co's shares  ANIX.O  rise 5.2% to $5 premarket
    ** Co reports advancing COVID-19 antiviral therapy candidate
to the next stage of development, based on preliminary data from
animal studies  urn:newsml:reuters.com:*:nPn8jvmCva
    ** Co and partner OntoChem are developing an oral,
room-temperature stable, anti-viral therapy candidate against
SARS-CoV-2 
    ** Companies expect next phase of development to take four
to five months
    ** Up to last close, ANIX stock up 55% this year 

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))